商品编号


EL-001-FP



品牌


Signosis



公司


Signosis



公司分类


Cell-Based Assays




1 Ea

商品信息

Description:
Epidermal? growth? factor? receptor? (EGFR)? is? a? cell-surface? receptor? with? intrinsic? intracellular? protein-tyrosine? kinase? (TK)? activity.? Ligand binding induces EGFR dimerization and phosphorylation, le
ADI
ng to the activation of EGFR signaling pathway.? In several malignancies?? such?? as?? non-small?? cell?? lung?? cancer (NSCLC),?? EGFR?? signaling?? is?? deregulated?? due?? to mutations? in? EGFR,? which? results? in? uncontrolled proliferation? and? migration? of? tumor? cells. EGFR mutations can lead to “oncogene-addicted” cancers, where the tumor cells depend on the mutated EGFR for cell survival and malignant phenotype.? One of the most?? common?? EGFR?? mutations?? found in human patients is L858R substitution in exon 21, within the activation loop of EGFR.??? Patients? with? this? mutation are sensitive to EGFR tyrosine kinase inhibitors (TKIs) such? as? gefitinib? or? erlotinib,? whereas? patients? with wild? type? EGFR? are? not? sensitive? to? TKI.??? Another clinically? relevant? mutation? associated? with? acquired gefitinib? and? erlotinib? resistance? is? T790M,? found? in exon? 20.??? Cells? expressing? EGFR? with? both? L858R and?? T790M?? mutations?? are?? resistant?? to?? induced apoptosis? in? the? presence? of? gefitinib? or? erlotinib.
Data:

Dose-dependent growth inhibition of BaF3 cells harboring EGFR exon 20 insertion D770-N771insSVD mutation (EL-008), control Ba/F3 cell line (EL-001) and EGFR exon 20, A767-dupASV mutation (EL-010). The cells were treated with the indicated dose of erlotinib for 72 hours and cell vi
ABI
lity was measured using
Signosis
CVC reagent.

?